CompScripts-Vet

What Are the Advantages of Social Media for Pharmacy Professionals?

Social media platforms are constantly changing and it is important to keep up with their evolution to optimize usage. Sometimes it is difficult to start. Many individuals only have personal Facebook accounts. What should you post and how often? Should you tweet or retweet? Share an article on LinkedIn or just like a post?

https://ryze.ly/53a3fe10

What Are the Advantages of Social Media for Pharmacy Professionals? As the profession moves more toward the internet, it is helpful to know how to best use the various platforms.

The Pharmacist’s Role in Bleeding Disorders

March is Bleeding Disorders Awareness Month, which gives pharmacists the opportunity to advocate for and honor patients with bleeding disorders. Having a bleeding disorder can put a patient at risk of a hemorrhage and death.

https://ryze.ly/092447d8

The Pharmacist’s Role in Bleeding Disorders Pharmacists are an important part of the care team for patients with bleeding disorders, providing services such as medication counseling and reconciliation.

How the Classification of Lymphoma Today Can Be Interpreted As a Marriage of Pathology, Genomics

Pharmacy Times interviewed Elaine Jaffe, MD, National Institutes of Health (NIH) distinguished investigator at the National Cancer Institute at NIH, who is receiving the American Society for Investigative Pathology Gold-Headed Cane Award and is presenting an award lecture at the Experimental Biology 2022 conference on the classification of lymphoma in the modern era—a marriage of pathology and genomics.

https://ryze.ly/178ab802

How the Classification of Lymphoma Today Can Be Interpreted As a Marriage of Pathology, Genomics Elaine Jaffe, MD, National Institutes of Health (NIH) distinguished investigator at the National Cancer Institute at NIH, discusses her American Society for Investigative Pathology Gold-Headed Cane Award lecture at the Experimental Biology 2022 conference on the classification of lymphoma in the mod...

Clincial Trials Show Niraparib Improves PFS With Tolerable Safety Profile Following Response to Platinum-based Chemotherapy in Ovarian Cancer

Niraparib (Zejula; Zai Lab Limited) showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) with a tolerable safety profile following a response to platinum-based chemotherapy regardless of biomarker status, according to the results of the phase 3 PRIME study presented at the Society of Gynecologic Oncology (SGO) annual meeting.1 The trial assessed niraparib as maintenance therapy in patients with newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, which were collectively termed ovarian cancer for the purposes of the study.

https://ryze.ly/0ca44af7

Clincial Trials Show Niraparib Improves PFS With Tolerable Safety Profile Following Response to Platinum-based Chemotherapy in Ovarian Cancer Niraparib shows promise in patients with newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.

FDA Approves Pembrolizumab for MSI‑H/dMMR Advanced Endometrial Carcinoma

The FDA has approved pembrolizumab (Keytruda) as a single agent for the treatment of patients with microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) advanced endometrial carcinoma, and who experienced disease progression after prior systemic therapy in any setting and who are not candidates for curative surgery or radiation.1

https://ryze.ly/442ae501

FDA Approves Pembrolizumab for MSI‑H/dMMR Advanced Endometrial Carcinoma Pembrolizumab (Keytruda) approved as a single agent for the treatment of patients with microsatellite instability–high or mismatch repair deficient advanced endometrial carcinoma.

Approaching Treatment of Newly Diagnosed or Recurrent Ovarian Cancer With PARP Inhibitors

Although the era of personalized medicine has arrived, there remains much to be discussed regarding platinum sensitive disease among patients with newly diagnosed or recurrent ovarian cancer, explained David O’Malley, MD, during a presentation at the Society of Gynecologic Oncology annual meeting. When looking at some of the market data, only approximately 40% of patients with platinum sensitive disease are receiving a poly (ADP-ribose) polymerase (PARP) inhibitor in the first-line setting.

https://ryze.ly/7d8d3cc6

Approaching Treatment of Newly Diagnosed or Recurrent Ovarian Cancer With PARP Inhibitors Only 40% of patients with platinum sensitive disease are receiving a PARP inhibitor in the first-line setting.